Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20.8M
-
Number of holders
-
368
-
Total 13F shares, excl. options
-
160M
-
Shares change
-
+3.19M
-
Total reported value, excl. options
-
$7.83B
-
Value change
-
-$144M
-
Put/Call ratio
-
0.46
-
Number of buys
-
216
-
Number of sells
-
-199
-
Price
-
$48.83
Significant Holders of Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) as of Q2 2018
473 filings reported holding NKTR - Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2018.
Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) has 368 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 160M shares
.
Largest 10 shareholders include FMR LLC (25.7M shares), PRIMECAP MANAGEMENT CO/CA/ (20.9M shares), VANGUARD GROUP INC (18.3M shares), BlackRock Inc. (12.7M shares), OppenheimerFunds, Inc. (11.6M shares), WELLINGTON MANAGEMENT GROUP LLP (6.82M shares), STATE STREET CORP (6M shares), JANUS HENDERSON GROUP PLC (4.9M shares), JPMORGAN CHASE & CO (2.14M shares), and Invesco Ltd. (2.12M shares).
This table shows the top 368 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.